Aardvark Therapeutics (AARD) Cash from Operations (2024 - 2026)
Aardvark Therapeutics (AARD) posted Cash from Operations of 18869000.0 for Q1 2026, down 12.25% sequentially from 16810000.0 in Q4 2025, and down 65.69% YoY from 54998764.27 in Q1 2025.
Aardvark Therapeutics (AARD) Cash from Operations (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Cash from Operations for 3 years, with the latest figure at 18869000.0 in Q1 2026.
- Quarterly Cash from Operations fell 65.69% year-over-year to 18869000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 61653000.0 (down 125.96% YoY) and the FY2025 annual result came in at 54172000.0, down 199.51% from the prior year.
- Cash from Operations declined to 18869000.0 in Q1 2026 per AARD's latest filing, from 16810000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2190000.0 in Q1 2024 and troughed at 18869000.0 in Q1 2026.
- A 3-year average of 10125333.33 and a median of 9844000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations sank 420.0% in 2025, then slumped 65.69% in 2026.
- Over 3 years, Cash from Operations stood at 7727000.0 in 2024, then tumbled by 117.55% to 16810000.0 in 2025, then dropped by 12.25% to 18869000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 18869000.0, 16810000.0, and 16130000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | -17.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.60 Mn |
| Jun 30, 2026 | -17.60 Mn |
| Mar 31, 2026 | -18.87 Mn |
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -16.81 Mn |
| Dec 31, 2025 | -16.81 Mn |
| Sep 30, 2025 | -16.13 Mn |
| Sep 30, 2025 | -16.13 Mn |
| Jun 30, 2025 | -9.84 Mn |
| Jun 30, 2025 | -9.84 Mn |
| Mar 31, 2025 | -11.39 Mn |
| Mar 31, 2025 | -11.39 Mn |
| Dec 31, 2024 | -7.73 Mn |
| Dec 31, 2024 | -7.73 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Sep 30, 2024 | -3.96 Mn |
| Jun 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -4.22 Mn |
| Mar 31, 2024 | -2.19 Mn |
| Mar 31, 2024 | -2.19 Mn |